Carl-Johan Dalsgaard, CEO of Vicore Pharma speaks to EPR about clinical trials of C21, an angiotensin II type 2 receptor agonist developed to treat rare lung diseases – and the first ever ATRAG to reach clinical-stage development.
Swedish pharmaceutical company Vicore Pharma is developing treatments for diseases where the angiotensin II type 2 receptor (AT2R) has a central role in stopping and reversing disease pathology and where there is a large unmet medical need. The company’s lead candidate, C21, is an angiotensin II type 2 receptor agonist (ATRAG). It represents a new class of drugs capable of reducing pulmonary inflammation, proliferation, fibrosis, and vasculopathy.
C21 is currently in Phase II clinical development for treatment of Idiopathic Pulmonary Fibrosis (IPF), a condition in which the lungs become scarred and breathing becomes increasingly difficult.
Vicore’s C21 is the first ever ATRAG reaching clinical stage”
“The AT2 receptor has been known for quite some time, but from a clinical point of view, it is a novel target, and Vicore’s C21 is the first ever ATRAG reaching clinical stage,” says Carl-Johan Dalsgaard, CEO of Vicore Pharma.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Reflecting on recent clinical milestones, Dalsgaard noted that in February Vicore presented efficacy data from its ongoing Phase II2a AIR clinical trial of C21 in IPF. This data, together with a favourable safety profile, make C21 a potential game-changer for IPF patients, particularly those who are currently not treated due to the side effects of the available drugs, according to Dalsgaard.
In May, Vicore reported new 36-week data from the AIR multi-centre clinical trial in a presentation at the American Thoracic Society (ATS) international congress.
With 51 patients enrolled in open label, single arm trial, Vicore says the trial data “demonstrates that C21 has the potential to transform the treatment of IPF and restore lung function.” The disease is currently considered to be incurable and inevitably progressive.
For example, at 36 weeks the average Forced Vital Capacity (FVC – a measure of lung capacity) of patients treated with C21 had increased to +350 mL over baseline, which is +530 mL over the expected trajectory of untreated patients (n= 19; p=0.001).
The magnitude of FVC stabilisation seen with C21 in the AIR trial is very different from what we normally see in clinical practice
Commenting on the significance of the findings, Professor Toby Maher, Keck School of Medicine at University of Southern California, stated: “The magnitude of FVC stabilisation seen with C21 in the AIR trial is very different from what we normally see in clinical practice and certainly gives hope for patients.”
He added that if data are replicated in the planned Phase IIb ANDAS trial, “there will be a fundamental change in how IPF is treated with an opportunity to stop progression and restore lung function.”
What are ATRAGs and how do they work?
The angiotensin II type 2 receptor agonist and the AT2 receptor represent an important component of the so-called renin-angiotensin-system.
Dalsgaard describes the system as an ancient “trauma rescue system,” with the main purpose of preventing blood pressure falling to levels, for example after injury with major blood loss. The main pathway for this is that the hormone angiotensin II binds to and activates the angiotensin type 1 receptor which leads to constriction of blood vessels and reduced fluid losses from the body. Activation of this type 1 receptor also promotes inflammation and thereby helps the immune system to fight infections, also common after injuries.
One drawback, however, is that the AT1 receptor pathway can overshoot and cause conditions eg, hypertension. There are several anti-hypertensive blood pressure drugs that either block the formation of angiotensin II or block the AT1 receptor.
This type 1 system has a parallel pathway that basically does the opposite via the angiotensin II type 2 receptor, the target of Vicore’s ATRAGs. Activating the AT2 receptor triggers resolution of tissue damaging processes and promotes repair in the damaged tissues, and this includes vasodilatory, anti-inflammatory and anti-fibrotic effects.
Developing and manufacturing C21
“ATRAGs represent a new class of drugs with enormous clinical and commercial potential considering that they activate a protective endogenous system of relevance for a long range of indications with unmet needs, including pulmonary, cardiovascular, renal, metabolic and CNS diseases,” Dalsgaard stated. C21 was also trialled in a study for patients with COVID-19.
In addition to the ongoing clinical trials above Vicore Pharma has initiated clinical proof-of-concept study of endothelial dysfunction – a key driver of organ damage associated with many diseases. Restoration of endothelial function may be both therapeutic and serve as an early efficacy biomarker in pulmonary, renal, vascular and several other diseases.
Reflecting on the development process, Dalsgaard highlighted a key challenge for small pharma companies: not being able to time-optimise the development path.
“To minimise gaps, investments for the next development phase are traditionally taken early, and back-up strategies are being executed in parallel tracks,” explains Dalsgaard. Vicore is shortening the development timelines and decreasing risk by having a collaborative operating model, an agile, creative and goal-oriented working environment, he adds.
Dalsgaard told EPR that 25kg pilot batches of the therapeutic have been produced without issues and Vicore expects scale-up to proceed successfully
When questioned about the manufacturing of the C21, Dalsgaard told EPR that 25kg pilot batches of the therapeutic have been produced without issues and Vicore expects scale-up to proceed successfully. The six-step C12 synthesis process is patent protected in the US and Europe, with patent applications filed in Japan, China and elsewhere.
The European Patent Office (EPO) granted Vicore’s patent (EP 4 138 789 B1) protecting an improved C21 formulation based on enteric coated compositions. The patent protects any form of enteric coating of C21 in Europe and is expected to last at least until 2041. The equivalent US patent was granted by the United States Patent and Trademark Office (USPTO) in June.
Commenting on the milestone Dalsgaard stated: “We are very pleased that this patent, providing strong protection for C21 in all diseases, has now been granted in both Europe and in the US. The European IPF market alone represents a large opportunity with 100,000 diagnosed patients. The combined US and European IPF market represent $3bn in annual sales. This patent also allows us to explore wider pulmonary fibrosis indications outside IPF as well as pulmonary hypertension.”
About the Interviewee
Carl-Johan Dalsgaard has been a Venture Partner at HealthCap since 2000, thereby he has served as CEO of several companies in which HealthCap has invested, including Vicore Pharma from 2018. Prior to that, he has ten years of experience from senior positions within the AstraZeneca Group, such as pre-clinical research director, therapeutic area manager of pain and anesthesia, CEO of Astra Pain Control AB and part of the Group’s research management team.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.